DRL Share Price: Dr Reddy’s results in the third quarter were better than expected. The company’s profit increased by two and a half percent. There was a 16 percent jump in the company’s revenue. The company got support from the acquisition of Nicotine Replacement Therapy business. However, there has been a decline of 2 percent in the margin. In the October-December quarter, the company’s net profit has increased by 2.5 percent on an annual basis. The company has earned a profit of Rs 1413 crore during this period. In the same quarter last year, this figure was Rs 1381 crore.
The market has not liked the company’s results. At 10.15 am today, the stock was seen trading at Rs 1230.70, down 4.55 per cent or Rs 58.70.
CLSA has given underperform rating on Dr Reddy’s. The target of its shares has been fixed at Rs 1120. The company’s US sales appear to be flat on an annual basis. But there was a decline in it on quarterly basis. The company may launch 15-20 products in the US during FY26/CY27. The company’s Indian business has seen strength. They have raised revenue and margin estimates for FY25-27
Top 20 Stocks Today- Investors and traders can make strong earnings in intraday by trading in these 20 stocks.
Citi has given a sell rating on Dr Reddy’s. The target of its shares has been fixed at Rs 1100. He says that the company has seen sluggish performance in Q3. Its results have been weaker than expected. Consolidation was seen in its NRT. EBITDA has been supported by lower R&D expenses on a quarterly basis. The company’s long-term commentary appears positive.
HSBC has given a hold rating on Dr Reddy’s. Its target has been fixed at Rs 1250. He says that revenue from integrated nicotine replacement therapy business was higher than expected. The launch of anti-diabetic drug semaglutide in Canada in early 2026 provides some relief to the company. However, the relief from semaglutide will not be enough to compensate for the Revlimid decline.
(Disclaimer: The views and investment advice expressed on Moneycontrol.com are the personal views and opinions of investment experts. Moneycontrol advises users to consult certified experts before taking any investment decision.)